Results 71 to 80 of about 20,494 (185)
Development of an N‑Terminal BRD4 Bromodomain-Targeted Degrader
, 2022 Targeted protein degradation is a powerful induced-proximity tool to control cellular protein concentrations using small molecules. However, the design of selective degraders remains empirical.
Taosheng Chen (298106) +8 more
core +1 more source
Genetic Investigation in Fetal Growth Restriction: An Integrated Approach for Clinical Practice
Prenatal Diagnosis, EarlyView.ABSTRACT International guidelines recommend genetic testing when fetal growth restriction (FGR) accompanies structural anomalies, but recommendations for apparently isolated FGR remain variable, particularly regarding gestational age thresholds and the role of exome sequencing (ES). Interpretation is difficult because studies define FGR inconsistently,
Eran Ashwal, David Chitayat
wiley +1 more source
Smart Molecules, EarlyView.AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source
, 2022 BRD4, a chromatin modifier frequently upregulated in a variety of neoplasms including hepatocellular cancer (HCC), promotes cancer cell growth by activating oncogenes through its interaction with acetylated histone tails of nucleosomes.
Robert J. Lee (299150) +8 more
core +1 more source
Loss of Brd4 alleviates pathological bone loss via Slc9b2 suppression in osteoclastogenesis
Clinical and Translational MedicineBackground Epigenetic regulation plays a crucial role in skeletal degenerative diseases, including osteoporosis. As an epigenetic reader, bromodomain protein 4 (Brd4) is known as a key driver of gene activation; however, its role in maintaining skeletal ...
Xiaohe Wang +14 more
doaj +1 more source
BRD9 inhibition as potential treatment option for testicular germ cell tumors
Andrology, EarlyView.Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen +5 more
wiley +1 more source
Brd4 is important for MCV DNA replication.
, 2012 A. Brd4 knockdown inhibits MCV replication in vivo. C33A cells were transfected with either a siRNA targeting Brd4 (K.D.) or a non-targeting siRNA control (C.O.). Forty-eight h later, cells were transfected with pT+Ori and this time was set as 0 h. Total
Jianxin You (121729) +5 more
core +1 more source
, 2022 BRD4, a chromatin modifier frequently upregulated in a variety of neoplasms including hepatocellular cancer (HCC), promotes cancer cell growth by activating oncogenes through its interaction with acetylated histone tails of nucleosomes.
Robert J. Lee (299150) +8 more
core +1 more source
Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA
Cell Reports, 2016 BRD4 governs pathological cardiac gene expression by binding acetylated chromatin, resulting in enhanced RNA polymerase II (Pol II) phosphorylation and transcription elongation. Here, we describe a signal-dependent mechanism for the regulation of BRD4 in
Matthew S. Stratton +10 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source